|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/496 | (2006.01) |
| A61K 31/496 | (2013.01) | ||
| A61K 31/675 | (2006.01) | ||
| A61P 27/06 | (2018.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 27/02 | (2018.01) | ||
| A61P 27/06 | (2006.01) |
| (11) | Number of the document | 3441069 |
| (13) | Kind of document | T |
| (96) | European patent application number | 18188799.3 |
| Date of filing the European patent application | 2018-08-13 | |
| (97) | Date of publication of the European application | 2019-02-13 |
| (45) | Date of publication and mention of the grant of the patent | 2023-04-05 |
| (46) | Date of publication of the claims translation |
| (30) | Number | Date | Country code |
| 201715675171 | 2017-08-11 | US | |
| 201762579793 P | 2017-10-31 | US |
| (72) |
Hopkins, Jill , US
Tsuruda, Pam , US
Chapman, Claude , US
Sweigard, Harry , US
Poon, Yan , US
Marquess, Daniel , US
David, Nathaniel , US
Dananberg, Jamie , US
Laberge, Remi-Martin , US
|
| (73) |
Unity Biotechnology, Inc. ,
285 East Grand Avenue, South San Francisco, CA 94080,
US
|
| (54) | TREATMENT OF DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| TREATMENT OF DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |